

Quetiapine Accord

MŖF

Accord Healthcare AB

Depottablett 50 mg

(persikofärgade, bikonvexa, filmdragerade tabletter, släta på ena sidan och präglade med "Q50" på den andra, $11.2 \times 11.2 \text{ mm}$)

Neuroleptika; diazepiner, oxazepiner och tiazepiner

Aktiv substans:

Kvetiapin

ATC-kod:

N05AH04

Läkemedel från Accord Healthcare AB omfattas av Läkemedelsförsäkringen.

Miljöpåverkan

Miljöinformationen för kvetiapin är framtagen av företaget AstraZeneca för Seroquel, Seroquel®

Miljörisk: Användning av quetiapin har bedömts medföra försumbar risk för miljöpåverkan.

Nedbrytning: Quetiapin bryts ned långsamt i miljön.

Bioackumulering: Quetiapin har låg potential att bioackumuleras.

Detaljerad miljöinformation

```
PEC/PNEC = 0.33 μg/L /10.0 μg/L = 0.033
PEC/PNEC \leq 0.1
```

Environmental Risk Classification

Predicted Environmental Concentration (PEC)

The PEC is based on following data:

PEC (
$$\mu$$
g/L) = (A*10⁹*(100-R))/(365*P*V*D*100)
PEC (μ g/L) = 1.37*10⁻⁶*A*(100-R)

PEC =
$$1.37 * 10^{-6} * 2430.60 * (100-0)$$

 $= 0.33 \, \mu g/L$

A (kg/year) = total sold amount API in Sweden year 2021, data from IQVIA/Lif

= 2430.60 kg/year

R (%) = removal rate (due to loss by adsorption to sludge particles, by volatilization, hydrolysis or

biodegradation)

= 0 (default)

P = number of inhabitants in Sweden = $10 * 10^6$

V (L/day) = volume of wastewater per capita and day = 200 (ECHA default)

D = factor for dilution of waste water by surface water flow = 10 (ECHA default)

Note: The factor 10^9 converts the quantity used from kg to μ g.

Metabolism

After oral administration, quetiapine is eliminated almost completely by metabolism, as < 1% of the dose is excreted with urine and faeces as unaltered parent. Approximately 73% of the dose is excreted as metabolites in urine and 21% is excreted in faeces. (Ref. 1)

Ecotoxicity data

| Study | Method | Result | Reference |
|--|--|--|-----------|
| Toxicity to Cyanobacterium (Blue-Green Alga) Microcy stis aeruginosa | US FDA Technical Assistance Document 4.01 | 21d NOEC _{growth} 32mg/L 21d LOEC _{growth} 64mg/L 21d NOEC _{cell density} 4.0mg /L 21d LOEC _{cell density} 8.0mg /L | 2 |
| Toxicity to Green Alga <i>Pse</i> udokirchneriella subcapitata (formerly known as Selenastrum capricornutum) | US FDA Technical Assistance Document 4.01 | 14d NOEC _{growth} = 2.5mg/L 14d LOEC _{growth} = 5.0mg/L 14d NOEC _{cell density} = 2.5mg/L 14d LOEC _{cell density} = 5.0mg/L | 3 |
| Chronic toxicitiy to <i>Daphni</i> a magna | US FDA Technical Assistance Document 4 09 | 21d LC50 > 32mg/L 21d NOEC = 18mg/L 21d LOEC = 32mg/L | 4 |
| Chronic toxicity to Midge Chironomus riparius | | 28d EC50 _{emergence} 465 mg/kg dry sediment 28d NOEC _{emergence} 125 mg/kg dry sediment 28d LOEC _{emergence} 250 mg/kg dry sediment | 5 |
| Acute toxicity to | | | |

| Study | Method | Result | Reference |
|--|--|--|-----------|
| , | |] | 6 |
| macrochirus | Assistance Document 4.11 | 96 h NOEC = 1.8mg/L | |
| Acute toxicity to Rainbow Trout <i>Oncorhynchus</i> <i>mykiss</i> | US FDA Technical Assistance Document 4.11 | 96 h LC50 = 22.0mg/L 96 h NOEC = 1.0mg/L | 7 |
| Early-life stage toxicity to Fathead Minnow <i>Pimephal</i> <i>es promelas</i> | IOECD 210 | 32 d NOEC = 0.1mg/L* 32 d LOEC = 0.32mg/L* | 8 |
| Activated sludge, respiration inhibition test | OECD209 | 3 hour EC50 $>$ 100mg/L 3 hour NOEC = 100mg/L | 9 |

^{*}The relevant effects measured were hatch, survival, length, wet and dry weight.

PNEC (Predicted No Effect Concentration)

Long-term tests have been undertaken for species from three trophic levels, based on internationally accepted guidelines. Therefore, the PNEC is based on the results from the chronic toxicity to fathead minnow (*Pimephales promelas*), the most sensitive species, and an assessment factor of 10 is applied, in accordance with ECHA guidance (ref. 10).

 $PNEC = 100 \mu g / L/10 = 10 \mu g/L$

Environmental risk classification (PEC/PNEC ratio)

 $PEC/PNEC = 0.33 \,\mu g/L / 10.0 \,\mu g/L = 0.033$

 $PEC/PNEC \le 0.1$ which justifies the phrase: "Use of Quetiapine has been considered to result in insignificant environmental risk."

In Swedish: "Användning av Quetiapin har bedömts medföra försumbar risk".

Environmental Fate Data

| Study | Method | Result | Reference |
|--|---------------------------|---|-----------|
| Poody hiodogradahility | | 28d Biochemical oxygen demand (BOD ₂₈) = 0% | |
| Ready biodegradability: Manometric respirometry | OECD 301F | 28d carbon loss= 10 % | 11 |
| | | 28d test substance loss = 24% | |
| | | Not readily biodegradable | |
| Anaerobic | UK DoE Modified | 0 % biodegradation 52% compound removal | |
| biodegradability | According to ISO/CD 11734 | by day 57 in anaerobic | 12 |
| | 11,51 | sludge | |
| | | $HOM DT_{50} (water) = 5.2d$ | |
| | | $LOM DT_{50} (water) = 18d$ | |
| | | HOM = 14.0% parent | |
| Aerobic transformation in aquatic sediment systems | OECD 308 | compound remaining at Day 101 | 13 |

| Study | Method | Result | Reference |
|---|--|---|-----------|
| | | LOM < 10% parent | |
| | | compound remaining at | |
| | | Day 101 | |
| Percentage Hydrolysis / Hydrolysis Half-life | US FDA Technical Assistance Document 3.09 | Hydrolysis at 50°C (at pH 5, 7 and 9, respectively) was <10% after 5 days. Estimated $DT_{50} \ge 1$ yr @ 25 °C | 14 |
| Adsorption and desorption to sewage sludge | OPPTS 835.1110 | Kd(ads) = 335 Kd(des) = 247 - 471 K = 905 L/Kg* | 15 |
| Soil adsorption and desorption | US FDA Technical Assistance Document 3.08 | Nebo (pH 4.9, OC 1.6%); Kd = 3600 L/Kg (Koc = 220,000 L/Kg) East Jubilee (pH 5.8, OC 2.2%); Kd = 180 L/Kg (Koc = 8,000 L/Kg) Kenny Hill (pH 7.7, OC 3.1%); Kd = 45 L/Kg (Koc = 1,400 L/Kg) | 16 |

^{*}Calculated $K_{oc} = K_{d(ads)} / 0.37$ (ref. 17)

Degradation

Aerobic biodegradation

A ready biodegradation test of quetiapine fumarate was undertaken by using aerobic microorganisms from a sewage treatment works to investigate their potential to readily degrade the substance. The test ended after 28 days. The results showed that quetiapine fumarate is not readily biodegradable.

Aerobic transformation in aquatic sediment systems

The degradation of quetiapine fumarate in aquatic sediment systems was assessed according to the OECD 308 Test Guideline. Two different sediments were used, one with high organic matter (HOM) and one with low organic matter (LOM) content over the 101 day test period.

In both, the high and low organic matter test vessels, quetiapine fumarate rapidly dissipated from the water phase and there was no evidence of mineralisation. In HOM sediment there was evidence to show that quetiapine fumarate was degraded, but there was insufficient analytical data to quantify the rate. The LOM sediment showed no evidence of quetiapine present. At the end of the study, <15% parent compound was reported to remain in the HOM system, with 14% remaining in the sediment phase and any remaining in the water phase being below the limit of quantification (LOQ) of 10%. The study reported no parent compound remaining in the LOM total system, indicating any parent compound residue was below the LOQ.

Based on the data available, the study passes the criteria for 'the substance is degraded in the environment' (DT_{50} of both systems is \leq 32 days and <15% parent remaining at the end of the study).

However, the whole system DT50s are not reported due to issues with the analytical method and the 101-day data point for the water phase in the HOM system is missing (and 1% or more of parent compound remaining in this sample would take the total amount of parent remaining above 15% for the HOM system). It is therefore considered appropriate to conservatively conclude that: 'Quetiapine is slowly degraded in the environment'.

In Swedish: 'Quetiapin bryts ned långsamt i miljön'.

Physical Chemistry Data

| Study | Method | Result | Reference |
|--|---|---|-----------|
| Solubility water | IAssistance Handbook 3 01 | 16 d @ pH 5 =10800 mg/L 20 d @ pH 7 =1600 mg/L 6 d @ pH 9 =360 mg/L | 18 |
| Solubility water | - | 3.29mg/mL | |
| Dissociation Constant | _ | pKa = 6.83 in phosphate buffer at 22C pKa = 3.32 in formic buffer at 22C | 19 |
| Octanol-Water Partition Coefficient | FDA Technical Assistance Handbook 3.02 | LogP = 0.5 | 20 |
| Partition coefficient | | LogDow = 1.4 @ pH 5 LogDow = 2.7 @ pH 7 LogDow = 2.6 @ pH 9 | |

Bioaccumulation

In the absence of a measured BCF value, since $LogD_{ow} < 4$ at pH 7 the substance has been assigned the phrase: 'Quetiapin has low potential for bioaccumulation'.

In Swedish: "Quetiapin har låg potential att bioackumuleras".

References

- 1. Investigator's Brochure Seroquel (Quetiapine fumarate; D1441000000) AstraZeneca. 13th edition, June 2008.
- 2. Seroquel: Toxicity to the blue-green alga Microcystis aeruginosa. BL5018/B. Brixham Environmental Laboratory, Brixham, UK. February 1994.
- **3.** Seroquel: Toxicity to the green alga Selenastrum capricornutum. BL5017/B. Brixham Environmental Laboratory, Brixham, UK. February 1994.
- **4.** Seroquel: Chronic toxicity to Daphnia magna. BL5232/B. Brixham Environmental Laboratory, Brixham, UK. September 1994.
- **5.** Quetiapine fumarate Toxicity to the sediment-dwelling phase of the midge Chironomus riparius. Report No. VKS0391/073509. Sponsors reference number: 06-0052/A. Huntingdon Life Sciences Ltd. UK. December 2007.
- **6.** Seroquel: Acute toxicity to bluegill sunfish (Lepomis macrochirus). BL5085/B. Brixham Environmental Laboratory, Brixham, UK. February 1994.
- 7. Seroquel: Acute toxicity to rainbow trout (Oncorhynchus mykiss). BL5084/B. Brixham Environmental Laboratory, Brixham, UK. February 1994.

- **8.** Quetiapine fumarate: Determination of effects on the early-life stage of the fathead minnow (Pimephales promelas). BL8351/B. Brixham Environmental Laboratory, Brixham, UK. August 2006.
- **9.** Quetiapine fumarate: Effect on the respiration rate of activated sludge. Report No. BL8333/B. Brixham Environmental Laboratory, Brixham, UK. June 2006.
- 10. Guidance on information requirements and chemical safety assessment. Chapter R.10: Characterisation of dose [concentration]-response for environment. European Chemicals Agency, 2008
- **11.** Seroquel: Determination of 28 day ready biodegradability. Report No. BL5078/B. Brixham Environmental Laboratory, Brixham, UK. February 1994.
- **12.** Seroquel: Determination of anaerobic biodegradability. Report No. BL5077/B. Brixham Environmental Laboratory, Brixham, UK. February 1994.
- **13.** Quetiapine fumarate: Aerobic transformation in aquatic sediment systems. BL8364/B. Brixham Environmental Laboratory, Brixham, UK. August 2007.
- **14.** Data generated in the US to support the environmental assessment report for ICI 204,636. Pharmaceutical research & development Report no. SP2900/B. BD4185 Zeneca Pharmaceuticals Group, Wilmington, USA. 29 March 1995.
- **15.** Quetiapine fumarate: Adsorption and desorption to sewage sludge. Report No. BL8343/B. Brixham Environmental Laboratory, Brixham, UK. August 2006.
- **16.** Seroquel: Soil sorption and adsorption. Report no. BL5062/B. Brixham Environmental Laboratory, Brixham, UK. February 1994.
- **17.** EUSES European Union System for the Evaluation of Substances 2.1 background report Model Calculations. 2019.
- **18.** ICI 204,636 solubility measurements in partial fulfillment of FDA environmental-assessment requirements. Pharmaceutical research & development report no. SP3010/B. BD4118. Zeneca Pharmaceuticals, Wilmington, USA. 22 September 1995.
- 19. S.1.3 General Properties, Quetiapine fumarate, ZD5077. Report no. BD4184
- **20.** ICI 204,636 log partition coefficient measurements in partial fulfillment of FDA environmental assessment requirements. Pharmaceutical research & development Report No. SP3011/B. BD4119. Zeneca Pharmaceuticals, Wilmington, USA. 3 October 1995.